Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October
27 sept. 2024 14h00 HE | Neurona Therapeutics
Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate
10 sept. 2024 16h05 HE | Neurona Therapeutics
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
26 juin 2024 16h05 HE | Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy
18 juin 2024 16h05 HE | Neurona Therapeutics
- RMAT designation follows positive data update from the ongoing Phase 1/2 clinical trial of NRTX-1001 cell therapy, demonstrating a favorable safety profile to date and the potential to significantly...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
11 juin 2024 16h05 HE | Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
28 mai 2024 08h00 HE | Neurona Therapeutics
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting
15 avr. 2024 08h00 HE | Neurona Therapeutics
NRTX-1001 administration has been well-tolerated in all individuals treated to date 4 of 5 subjects treated with the lower dose of NRTX-1001 report >50% seizure reduction 3 of 5 subjects report...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics to Present at Stifel 2024 Virtual CNS Days
12 mars 2024 16h00 HE | Neurona Therapeutics
SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Announces Presentation of Updated Clinical Data at the Upcoming American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001
07 mars 2024 16h00 HE | Neurona Therapeutics
Neurona Therapeutics to present updated clinical data from NRTX-1001 investigational cell therapy program at AAN Annual Meeting
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders
08 févr. 2024 08h00 HE | Neurona Therapeutics
$120M financing will support advancement of ground-breaking regenerative cell therapies for chronic CNS disorders